CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2500
+0.0100 (4.17%)
Feb 5, 2026, 4:00 PM EST
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
-$3,103,462
Market Cap
313.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | 24 | 5 | 26.32% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
CytoDyn News
- 9 days ago - CytoDyn Secures Funding To Launch Expanded Access Program For Leronlimab In Breast Cancer - Nasdaq
- 10 days ago - CytoDyn (CYDY) Secures Funding for Breast Cancer Program - GuruFocus
- 10 days ago - CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer - GlobeNewsWire
- 7 weeks ago - CytoDyn (CYDY) Anticipates Significant Progress in 2026 - GuruFocus
- 7 weeks ago - December 2025 Letter to Shareholders - GlobeNewsWire
- 2 months ago - CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - CytoDyn Announces Resolution of Class Action Lawsuit - GlobeNewsWire
- 2 months ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire